The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.

Proc Natl Acad Sci U S A

Structural Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook 2, 12441 Parklawn Drive, Rockville, MD 20852, USA.

Published: February 2008

AI Article Synopsis

  • The PD-1 receptor binds to its ligand PD-L1, which inhibits immune responses and maintains immune tolerance, impacting how the body fights tumors and viruses.
  • Researchers presented the crystal structure of murine PD-1 paired with human PD-L1, revealing how their IgV domains interact similarly to antibodies and T cell receptors.
  • This study identifies key residues crucial for the PD-1/PD-L1 binding, suggesting potential therapeutic approaches using antibodies or small molecules to enhance immune responses by blocking their interaction.

Article Abstract

Signaling through the programmed death 1 (PD-1) inhibitory receptor upon binding its ligand, PD-L1, suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance. Release from PD-1 inhibitory signaling revives "exhausted" virus-specific T cells in chronic viral infections. Here we present the crystal structure of murine PD-1 in complex with human PD-L1. PD-1 and PD-L1 interact through the conserved front and side of their Ig variable (IgV) domains, as do the IgV domains of antibodies and T cell receptors. This places the loops at the ends of the IgV domains on the same side of the PD-1/PD-L1 complex, forming a surface that is similar to the antigen-binding surface of antibodies and T cell receptors. Mapping conserved residues allowed the identification of residues that are important in forming the PD-1/PD-L1 interface. Based on the structure, we show that some reported loss-of-binding mutations involve the PD-1/PD-L1 interaction but that others compromise protein folding. The PD-1/PD-L1 interaction described here may be blocked by antibodies or by designed small-molecule drugs to lower inhibitory signaling that results in a stronger immune response. The immune receptor-like loops offer a new surface for further study and potentially the design of molecules that would affect PD-1/PD-L1 complex formation and thereby modulate the immune response.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268576PMC
http://dx.doi.org/10.1073/pnas.0712278105DOI Listing

Publication Analysis

Top Keywords

pd-1/pd-l1 complex
12
antibodies cell
12
cell receptors
12
igv domains
12
domains antibodies
8
pd-1 inhibitory
8
inhibitory signaling
8
pd-1/pd-l1 interaction
8
immune response
8
pd-1/pd-l1
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!